帕金森病合并睡眠障碍应用卡比多巴-左旋多巴控释片治疗的临床分析
|
摘要
目的:分析卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍的临床效果。方法:选取2010年1月至2018年12月厦门市第五医院神经内科收治的帕金森合并睡眠障碍患者32例,按照随机数字表法随机分为观察组和对照组,每组16例。对照组给予常规治疗,观察组在对照组基础上给予多巴-左旋多巴控释片治疗。比较2组患者的帕金森病情变化、睡眠质量变化和不良反应发生情况。结果:2组患者治疗前UPDRS评分比较,差异无统计学意义(P> 0. 05),治疗后观察组的UPDRS评分显著低于对照组(P <0. 05)。2组患者治疗前PSQI评分比较,差异无统计学意义(P> 0. 05),治疗后观察组患者的PSQI评分显著低于对照组(P <0. 05)。对照组不良反应发生率为6. 25%,观察组不良反应发生率为12. 5%,2组比较差异无统计学意义(P> 0. 05)。结论:卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍的临床效果确切,且安全性高。
Objective: To analyse the effect of Carbidopa-Levodopa Controlled Release Tablets in the Treatment of Parkinson's Disease Complicated with Sleep Disorder. Methods: From January 2010 to December 2018,32 patients with Parkinson' s disease and sleep disorder were randomly divided into obervation group and control group,16 in each group. The control group was given routine treatment,while the obervation group was given dopa-levodopa controlled-release tablets on the basis of the control group. The changes of Parkinson's disease,sleep quality and adverse reactions were compared between the two groups. Results: There was no difference in UPDRS score between the two groups before treatment. After treatment,UPDRS score of the obervation group was significantly lower than that of the control group( P < 0. 05). There was no difference in PSQI score between the two groups before treatment. After treatment,PSQI score of the obervation group was significantly lower than that of the control group( P < 0. 05). The incidence of adverse reactions was 6. 25% in the control group and 12. 5% in the obervation group. There was no significant difference between the two groups( P > 0. 05). Conclusion: Carbidopa-levodopa controlled-release tablets are effective and safe in the treatment of Parkinson's disease with sleep disorders.
Objective: To analyse the effect of Carbidopa-Levodopa Controlled Release Tablets in the Treatment of Parkinson's Disease Complicated with Sleep Disorder. Methods: From January 2010 to December 2018,32 patients with Parkinson' s disease and sleep disorder were randomly divided into obervation group and control group,16 in each group. The control group was given routine treatment,while the obervation group was given dopa-levodopa controlled-release tablets on the basis of the control group. The changes of Parkinson's disease,sleep quality and adverse reactions were compared between the two groups. Results: There was no difference in UPDRS score between the two groups before treatment. After treatment,UPDRS score of the obervation group was significantly lower than that of the control group( P < 0. 05). There was no difference in PSQI score between the two groups before treatment. After treatment,PSQI score of the obervation group was significantly lower than that of the control group( P < 0. 05). The incidence of adverse reactions was 6. 25% in the control group and 12. 5% in the obervation group. There was no significant difference between the two groups( P > 0. 05). Conclusion: Carbidopa-levodopa controlled-release tablets are effective and safe in the treatment of Parkinson's disease with sleep disorders.
引文
[1]罗小丹,禤彩霞,杨开杰,等.普拉克索联合复方多巴治疗中晚期帕金森病的临床观察[J].医药前沿,2016,6(7):145-146.
[2]蒋雨平,王坚,丁正同,等.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40.
[3]周红杰,蒋晓江,李玮,等.帕金森患者睡眠障碍临床特点及相关因素分析[J].重庆医学,2009,38(10):1163-1165.
[2]蒋雨平,王坚,丁正同,等.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40.
[3]周红杰,蒋晓江,李玮,等.帕金森患者睡眠障碍临床特点及相关因素分析[J].重庆医学,2009,38(10):1163-1165.